Supplementary Table 2. Medication at discharge in patients who survived to discharge.
| Variable | J-HBR (n= 498) | No J-HBR (n= 492) | p value |
|---|---|---|---|
| Antiplatelet therapy | |||
| Aspirin | 441 (88.6%) | 491 (99.8%) | ＜0.001 |
| Clopidogrel | 260 (52.2%) | 187 (38.0%) | ＜0.001 |
| Prasugrel | 199 (40.0%) | 295 (60.0%) | ＜0.001 |
| Oral anticoagulation | 112 (22.5%) | 0 (0%) | ＜0.001 |
| ACE-I/ARB | 391 (78.5%) | 434 (88.2%) | ＜0.001 |
| β-blocker | 336 (67.5%) | 389 (79.1%) | ＜0.001 |
| Statin | 435 (87.4%) | 464 (94.3%) | ＜0.001 |
| NSAIDs/steroids | 49 (9.8%) | 15 (3.1%) | ＜0.001 |
| PPI | 468 (94.0%) | 473 (96.1%) | 0.14 |
| H2-blocker | 14 (2.8%) | 7 (1.4%) | 0.18 |
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; J-HBR, the Japanese version of the high bleeding risk; NSAIDs, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor.